Lilly Reveals Q3 2025 Financials, Boosts 2025 Outlook with R&D Advances
El-Balad reports on Eli Lilly and Company’s impressive performance in the third quarter of 2025, revealing a significant revenue increase driven by product demand. The company announced a 54% rise in revenue, amounting to $17.60 billion, largely attributed to strong sales of Mounjaro and Zepbound.
Lilly’s Q3 2025 Financial Highlights
Eli Lilly recorded substantial growth in its earnings per share (EPS) during Q3 2025. Reported EPS rose to $6.21, up from $1.07 in the same period last year. On a non-GAAP basis, EPS reached $7.02, compared to $1.18 in Q3 2024.
Revenue Breakdown and Key Products
- Revenue Sources:
- Revenue in the U.S. surged by 45% to $11.30 billion.
- International sales increased by 74%, reaching $6.30 billion.
- Key Products:
- Mounjaro: Revenue of $6.52 billion, a 109% increase.
- Zepbound: Revenue soared to $3.59 billion, marking an 184% rise.
- Verzenio: Revenue grew by 7% to reach $1.47 billion.
Overall, the significant volume growth for these products has greatly influenced Lilly’s financial outlook.
Increased 2025 Guidance
Lilly has revised its full-year revenue guidance for 2025 to between $63.0 billion and $63.5 billion. The EPS forecast has also been elevated, now projected between $21.80 and $22.50 on a reported basis and between $23.00 and $23.70 on a non-GAAP basis.
Advancements in Research and Development
During this quarter, Lilly made notable progress in its pipeline. The company achieved positive results from four Phase 3 trials of orforglipron, targeting type 2 diabetes and obesity. Additionally, it plans to submit data to global regulatory authorities by year-end for obesity treatment.
Regulatory Approvals
- The U.S. FDA approved Inluriyo (imlunestrant) for specific adult patients with advanced or metastatic breast cancer.
- Lilly’s Omvoh and Kisunla received significant regulatory milestones, further enhancing their portfolio.
Manufacturing Expansion
Lilly announced the opening of new facilities in Virginia and Texas, along with the expansion of its site in Puerto Rico, aimed at increasing its manufacturing capabilities.
Conclusion
Eli Lilly’s Q3 2025 financial results reflect a robust performance, supported by strong product demand and strategic advancements in R&D. With revised guidance for the remainder of the year, the company is positioned for continued growth and innovation in the pharmaceutical industry.
